Freenome disclosed validation results for an updated version of its SimpleScreen CRC blood test, reporting that the assay met primary and secondary endpoints in a large clinical validation dataset drawn from its PREEMPT CRC registrational study. The study enrolled 48,995 asymptomatic, average-risk adults scheduled for colonoscopy across more than 200 sites. Freenome reported overall sensitivity of 80.4% and specificity of 90%, with sensitivity varying by lesion type and cancer stage—for example, 100% sensitivity for stage IV cancers and 97.3% for stage III. The updated test slightly reduced overall sensitivity versus the earlier version (81.1%), but improved detection of advanced precancerous lesions and high-grade dysplasia. The company framed the revision as improving early detection and prevention outcomes, while investors will now look for how the sensitivity profile translates into clinical use and potential future regulatory submissions.